Become a Creator today!Start creating today - Share your story with the world!
Start for free
00:00:00
00:00:01
ECB reaction, China’s innovation, COVID-19 vaccines - HSBC Global Research
19 Plays4 years ago
In this edition we discuss the key takeaways from the latest ECB meeting, assess how China is aiming to improve its scientific research capabilities and consider new data about COVID-19 antibody protection. Disclaimer:
To stay connected and to access free to view reports and videos from HSBC Global Research click here
Hosted on Acast. See acast.com/privacy for more information.
Recommended
Transcript
Podcast Introduction
00:00:00
Speaker
This is HSBC Global Viewpoint, your window into the thinking, trends and issues shaping global banking and markets.
00:00:09
Speaker
Join us as we hear from industry leaders and HSBC experts on the latest insights and opportunities for your business.
00:00:17
Speaker
Thank you for listening.
00:00:27
Speaker
Hello and welcome to the Macro Viewpoint by HSBC Global Research, our weekly podcast featuring the views of leading HSBC analysts on the outlook for the global economy and markets.
00:00:37
Speaker
I'm Piers Butler and I'm joined by Chris Brown-Hunes.
ECB Meeting Highlights
00:00:39
Speaker
Hi Piers, coming up in this week's programme, the ECB has just held its latest meeting.
00:00:44
Speaker
We get the key takeaways from Fabio Balboni, senior European economist.
00:00:48
Speaker
We look at how China is aiming to improve its scientific research capabilities and
00:00:52
Speaker
with Erin Chin, Greater China Economist.
00:00:55
Speaker
And Steve McGarry, Global Head of Healthcare Research, looks at some worrying new data about how antibody protection can wane with certain COVID-19 vaccines over time.
00:01:04
Speaker
This podcast was recorded on Thursday, the 22nd of July, 2021.
00:01:08
Speaker
Our full disclosures and disclaimers can be found in the link attached to this podcast.
00:01:17
Speaker
We begin this week in Europe, where the ECB has just held its latest policy meeting.
00:01:22
Speaker
Fabio Balberni, senior European economist, is here to give us the details.
00:01:26
Speaker
So, Fabio, the ECB recently announced a new inflation target, and hence today it changed its forward guidance in the light of that.
00:01:34
Speaker
What did we learn?
00:01:35
Speaker
Yes, Chris, indeed.
00:01:36
Speaker
So the forward guidance was changed today.
00:01:39
Speaker
And there's three main elements of it.
00:01:41
Speaker
So the ECB is now saying they will not increase rates, so they will keep rates at current or lower level until when inflation has hit the new 2% target.
00:01:53
Speaker
So of course, the inflation target was revised up from below, but close to 2% to 2%.
00:01:58
Speaker
So that was factored in the new forward guidance.
00:02:01
Speaker
And that inflation target has to be met well ahead into the forecast horizon.
00:02:08
Speaker
And Christine Lagarde said during the meeting that that well ahead means by the midpoint of the inflation horizon.
00:02:16
Speaker
So for example, currently the inflation horizon goes until the end of 2023.
00:02:21
Speaker
So that will be at some point next year, in the second half of next year.
00:02:26
Speaker
And that inflation has to be sustainably at those level after that.
00:02:31
Speaker
And then in any case, there will have to be a judgment by the governing council that sufficient progress has been made towards achieving that target.
00:02:40
Speaker
So quite a strengthening of forward guidance related to what we had before, which was only a commitment to keep rates at current or lower level until when inflation adds sustainably.
00:02:53
Speaker
met the target.
00:02:55
Speaker
So does this tell us any more about the time when the ECB might start raising rates?
00:03:00
Speaker
Well, look, our expectation has been that it would have taken a long time for the ECB to increase rates.
00:03:05
Speaker
We said we didn't expect any increase of rates until 2023.
00:03:09
Speaker
And the market was instead pricing in the first rate hike by 2023, already 10 basis points.
00:03:17
Speaker
So we think that should definitely push
00:03:19
Speaker
market expectation for the first rate increase towards our view.
00:03:25
Speaker
And as I said before, the midpoint of the inflation forecast at the moment is around the second half of 2022.
00:03:33
Speaker
But by the time we get to December, then the ECB will introduce 2024.
00:03:37
Speaker
And that will move the midpoint of the inflation forecast around mid-2023.
00:03:45
Speaker
And for example, at the moment, the ECB is only forecasting inflation at
00:03:49
Speaker
1.4% then.
00:03:51
Speaker
So you can see that we're still significantly far off the 2% that ECB is aiming to achieve and in a sustainable manner.
00:04:00
Speaker
And what about the asset purchases aspect?
00:04:03
Speaker
Because at the moment we're currently expecting an announcement on tapering to come as early as this September.
00:04:08
Speaker
Yes, indeed.
00:04:09
Speaker
Today, asset purchases were not discussed.
00:04:11
Speaker
Christine Lagarde made that point clearly.
00:04:14
Speaker
We weren't expecting an explicit discussion.
00:04:16
Speaker
The ECB had said they would reassess asset purchases under the Pandemic Emergency Purchase Program, or PEP, every three months.
00:04:24
Speaker
So they did that in June.
00:04:25
Speaker
And Christine Lagarde said that there would be a reassessment in September.
00:04:30
Speaker
Our expectation is that they would taper asset purchases in September, but there is a big uncertainty.
00:04:36
Speaker
It is possible that the ECB, if they want to show a bigger commitment towards achieving the new inflation target, they might decide not to taper purchases.
00:04:44
Speaker
They could also decide to extend the program, particularly if you are in a new wave of the pandemic.
00:04:51
Speaker
But in general, Christine Lagarde has made the point and reinforced it today that the ECB response will be forceful
00:04:59
Speaker
and persistent.
00:05:00
Speaker
So that remains in line with our view that no matter what happens to PEP, we will see asset purchases continue for a long period of time.
00:05:10
Speaker
And we should see also the asset purchases under the normal QE programs be stepped up in the future.
00:05:17
Speaker
That's great, Fabio.
00:05:18
Speaker
Thank you very much for joining us today.
00:05:20
Speaker
Thank you very much.
China's R&D Progress
00:05:24
Speaker
This week, our Asia economics team kicked off a series of reports on China's innovation through to 2025.
00:05:29
Speaker
The first report looks at how the country is improving its scientific research capabilities.
00:05:34
Speaker
Erin Shin is our Greater China Economist, and she joins us now.
00:05:37
Speaker
So Erin, China's obviously made a lot of progress in terms of scientific research in recent years.
00:05:43
Speaker
What are the areas where you feel it's doing particularly well?
00:05:47
Speaker
So China's made a lot of progress in terms of its R&D.
00:05:50
Speaker
And in terms of its investment, it's actually the second largest globally.
00:05:55
Speaker
It accounts for over 20% of the global spending in R&D currently.
00:06:01
Speaker
And also combined with its strong talent development, we've seen that China's been able to top the rankings in terms of innovation.
00:06:11
Speaker
So in the global innovation index, China is now the only emerging market among the top 20.
00:06:17
Speaker
And since 2019, China has also topped world rankings for the patent applications.
00:06:25
Speaker
Now, we also did a deep dive into where China has some strengths.
00:06:30
Speaker
And we found that looking at the academic rankings among the top 100 universities, China has made a lot of progress in the engineering fields.
00:06:39
Speaker
So China actually has the leading global share
00:06:43
Speaker
among over half of the engineering fields that we looked at.
00:06:47
Speaker
So this is 12 out of 22 of them.
00:06:49
Speaker
So you say it's doing well on the engineering field side, but there are other areas that you've identified where it's not doing quite so well.
00:06:56
Speaker
Yeah, that's correct.
00:06:57
Speaker
So also looking at the academic rankings, we see that among the other sciences, such as natural sciences, life sciences and medical sciences, China's still falling pretty far behind.
00:07:09
Speaker
So it only accounts for about 10% or less generally in these fields.
00:07:15
Speaker
And this is pretty far behind Europe and the US, which can account for anywhere from 30% to 50% in each field, depending on the field.
00:07:24
Speaker
And if China's to make further progress, what do you feel the next steps are?
00:07:28
Speaker
So we think that China is going to take a two-pronged approach.
00:07:32
Speaker
The first one is domestically, we do think that they want to double down on basic research and
00:07:40
Speaker
In the 14th five-year plan, they've set a target to increase the share from the current level of 6% to over 8% of total R&D spending into basic research.
00:07:51
Speaker
So we think that they're going to increase the funding for building national laboratories, as well as talent development programs, as well as giving some more tax incentives to increase basic research funding.
00:08:04
Speaker
Now, the other approach that we see is they're going to increase international collaboration.
00:08:08
Speaker
because it makes more sense that China can close the knowledge gap by learning from others as opposed to reinventing the wheel.
00:08:17
Speaker
So we see China deepening its international collaboration by closing trade and investment deals, as well as implementing more opening and reform to help level the playing field, increasing intellectual property rights enforcement to increase investment and R&D spending in China.
00:08:35
Speaker
Now we also see China looking to become more attractive,
00:08:39
Speaker
for foreign talent.
00:08:40
Speaker
And this can be done by providing personal tax exemptions to be more competitive globally, as well as providing more social services for foreign talent, such as housing subsidies, competitive wages, education for their children as well.
00:08:58
Speaker
Erin, thank you very much indeed for that summary.
00:09:00
Speaker
Thank you, Chris.
00:09:04
Speaker
Now we finish off with a look at some new data that's been published regarding the antibody protection levels of some of the COVID-19 vaccines.
COVID-19 Vaccine Insights
00:09:12
Speaker
Stephen McGarry, Global Head of Healthcare Research, is here to explain.
00:09:17
Speaker
Steve, welcome to the podcast.
00:09:19
Speaker
Thank you.
00:09:20
Speaker
So you've just published a report highlighting that there is a new paper in the medical journal, The Lancet, which has some important data on COVID-19 antibodies
00:09:31
Speaker
were getting from vaccination.
00:09:33
Speaker
Can you tell us a bit more about that?
00:09:34
Speaker
And also just remind the listeners as to the significance of a paper appearing in The Lancet.
00:09:40
Speaker
Sure thing.
00:09:40
Speaker
The Lancet is one of the most prestigious medical journals in the world.
00:09:44
Speaker
Papers only appear there if they've been rigorously peer-reviewed.
00:09:48
Speaker
So when papers come out there, basically the medical and scientific community take notice.
00:09:53
Speaker
The data, the new data, was looked at protective antibodies that have been generated by COVID-19 vaccines over time.
00:10:02
Speaker
And what it shows is that after the second dose, which get of each of either the Pfizer vaccine or the AstraZeneca vaccine, and it's the second dose that gives you the full protection, antibody levels actually decline quite a lot up to about day 70 after the second protective dose.
00:10:19
Speaker
And we're just highlighting that this has now been published and it's something that we need to take note of in terms of how long vaccine efficacy might last.
00:10:28
Speaker
And it looks like, from what you say, that it does matter which vaccine you receive.
00:10:34
Speaker
It does indeed.
00:10:34
Speaker
I think the first thing to say is that it doesn't really matter which of the approved vaccines you get.
00:10:38
Speaker
They're all very effective and likely to remain fairly effective or very effective for some time to come.
00:10:45
Speaker
But we do know that the Pfizer and Moderna vaccines give you about 95% protection.
00:10:51
Speaker
The AstraZeneca vaccine, which has been predominantly used in the UK, gives you about 62% protection after the second dose.
00:10:59
Speaker
However, what this paper points out is that the protective antibody levels are much higher with the Pfizer vaccine than the Astra vaccine.
00:11:07
Speaker
And therefore, when you get significant declines in protective antibodies, you're likely to get, by the looks of it, better protection longer term if you've got the Pfizer vaccine relative to the AstraZeneca vaccine.
00:11:19
Speaker
And obviously, if you get less protection with the Astra vaccine to begin with, the question then becomes at what level or at what point or could this happen?
00:11:28
Speaker
that you reach a level where those antibodies no longer protect you as well against COVID-19 and especially new variants of COVID-19 like the Delta variant.
COVID-19 Restrictions and Impact
00:11:37
Speaker
Yes, you mentioned the Delta variant and indeed these conclusions have some significant implications, particularly as the UK has moved to lift most COVID-19 restrictions.
00:11:48
Speaker
Potentially it will do.
00:11:48
Speaker
I mean, if you look at what causes COVID-19 to be transmitted, it's
00:11:53
Speaker
it's closer contact, the lifting of restrictions will mean there is more contact between people in a broad range of settings.
00:12:01
Speaker
Some of those settings would cause increased transmissions, for example, if you go to the beach or you're outside settings, but in crowded indoor settings, lifting of restrictions raises the risk that you do get more transmission.
00:12:14
Speaker
The more transmission you get and the greater exposure to the virus, even if you've been vaccinated, means that you can either pass it on to unvaccinated or clinically vulnerable people
00:12:23
Speaker
Or there's also the risk that even despite vaccination, you could become infected with something like the Delta variant that could still cause illness.
00:12:31
Speaker
And there's always a lag effect.
00:12:33
Speaker
So how long before we know the impact on hospitalisation and mortality?
00:12:40
Speaker
It's a really difficult one to call for the time being.
00:12:43
Speaker
What we saw in the winter, the third peak in winter, there was about a three-week lag between COVID.
00:12:49
Speaker
the peak of the number of infections and the peak of hospitalizations and deaths.
00:12:54
Speaker
Hopefully, and the initial data looks as if this is encouraging, with vaccines having been deployed in a large part of the population in the UK, that gap will become wider.
00:13:06
Speaker
And what's more, the number of hospitalizations and deaths will be significantly more than we saw during the pre-vaccination period.
00:13:13
Speaker
But we'll need to monitor this on a day-to-day basis over the coming months.
00:13:18
Speaker
as the data rolls in every single day.
00:13:20
Speaker
Steve, thank you very much indeed.
00:13:22
Speaker
Thank you.
Podcast Conclusion
00:13:23
Speaker
That brings us to the end of today's Macro Viewpoint.
00:13:26
Speaker
Thank you to our guests, Fabio Balboni, Aaron Shin and Steve McGarry.
00:13:30
Speaker
From Piers and me, thanks very much for listening.
00:13:32
Speaker
We'll be back again next week.
00:13:41
Speaker
Thank you for listening today.
00:13:42
Speaker
This has been HSBC Global Viewpoint Banking and Markets.
00:13:47
Speaker
For more information about anything you heard in this podcast or to learn about HSBC's global services and offerings, please visit gbm.hsbc.com.